免疫检查点抑制剂引起的风湿学不良事件。
Rheumatological adverse events secondary to immune checkpoint inhibitors.
发表日期：2023 Mar 31
作者：
María Cecilia Garbarino, Natalia Manzano, Osvaldo Messina, Marcelo Zylberman
来源：
Immunity & Ageing
摘要：
2010年描述了一组名为免疫检查点抑制剂的药物治疗癌症的第一次经历。它们目前用于许多肿瘤治疗，具有成功的生存结果，但也出现了新的副作用证据。这种全新的免疫介导毒性谱系包括T淋巴细胞的过度炎症反应以及自身免疫疾病或类似病理的发展。其中，风湿毒性尤为值得注意。本文旨在提醒内科医生和风湿病学家对其认知和临床管理。版权所有©2023。由Elsevier España，S.L.U.出版。
The first experiences with a group of drugs called immune checkpoint inhibitors for the treatment of cancer were described in 2010. They are currently used in many tumours, with successful survival outcomes but a new profile of adverse events. This new spectrum of immune-mediated toxicities includes an exaggerated inflammatory response of T lymphocyte and the development of autoimmune diseases or similar pathologies. Of these, of particular note are the rheumatological toxicities. This review aims to alert internists and rheumatologists to their recognition and clinical management.Copyright © 2023. Published by Elsevier España, S.L.U.